OB
Chronic Hypertension in Pregnancy
search
Chronic Hypertension in Pregnancy
See Also
Gestational Hypertension
Hypertensive Disorders of Pregnancy
PIH Prophylaxis
Mild PIH Management
Severe PIH Management
PIH Blood Pressure Management
Definitions
Chronic Hypertension in Pregnancy
Chronic
Hypertension
(140/90 mmHg) that extends into pregnancy without
Preeclampsia
Onset of
Hypertension
before 20 weeks gestation or persisting beyond 12 weeks after delivery
Superimposed
Preeclampsia
complicates 17 to 25% of chronic
Hypertension
patients in pregnancy
Risk Factors
Superimposed
Preeclampsia
Risk Factors in Chronic
Hypertension
Age 35 years or higher
Antihypertensive
needed for
Blood Pressure
control
History of prior pregnancy complications
Preeclampsia
Untrauterine growth retardation
Intrauterine Fetal Demise
Comorbid conditions
Diabetes Melllitus
Systemic Lupus Erythematosus
Chronic cardiopulmonary disease
Renal disease
Abnormal labs
Serum Creatinine
>1.0 mg/dl
Proteinuria
>300 mg/24 hours
Phopholipid
Antibody
positive
Precautions
Chronic Hypertension in Pregnancy
Observe for superimposed
Preeclampsia
on chronic
Hypertension
High index of suspicion if maked
Blood Pressure
increase or new onset
Proteinuria
Chronic
Hypertension
history for >10 years is a risk for underlying heart disease and cardiovascular complications
Cardiomyopathy
including cardiomegaly and ventricular hypertrophy
Coronary Artery Disease
Labs
Baseline
Hypertension
labs may be obtained prior to pregnancy or during pregnancy
Standard
Hypertension
testing
Complete Blood Count
with
Platelet Count
Serum
Electrolyte
s including
Serum Potassium
Serum Creatinine
and
Blood Urea Nitrogen
Spot
Urine Protein to Creatinine Ratio
(or
24 Hour Urine Protein
)
Thyroid Stimulating Hormone
(if not recently obtained, typically part of
Prenatal Lab
s)
Other labs (consider as baseline when other labs are drawn, given PIH risk)
Serum transaminases (AST, ALT)
Diagnostics
Electrocardiogram
(EKG) indications
Age >30 years
Poorly controlled chronic
Hypertension
>4 years
Echocardiogram
Abnormal EKG
Cardiopulmonary signs or symptoms
Obsetetric
Ultrasound
in third trimester
Chronic
Hypertension
is associated with
Intrauterine Growth Retardation
(
IUGR
)
Monitoring
Indicated in chronic
Hypertension
requiring medications
Weekly
Fetal Monitoring
starting at 32 weeks
Estimate amniotic fluid index (AFI) weekly
Non-Stress Test
(NST) 1-2 times weekly
Biophysical Profile
(BPP) if NST not reactive
Further evaluation if BPP <8
Management
Gene
ral
See
PIH Blood Pressure Management
See
Anti-Hypertensive Medications in Pregnancy
Despite early studies,
Aspirin
DOES lower
Preeclampsia
risk and
Intrauterine Growth Retardation
risk
See
Preeclampsia Prevention
Aspirin
81 mg orally daily starting at 12-28 weeks and continuing until delivery
Hypertension
therapy during pregnancy does not reduce pregnancy complications
However, persistent
Hypertension
does have adverse effects on maternal health and is treated as below
Evidence supports medication management of mild Chronic Hypertension in Pregnancy
Antihypertensive
s appropriate for pregnancy are not associated with fetal or maternal pregnancy complications
See
Antihypertensive
s below
Low Sodium Diet
shows no benefit
Minimizing weight gain shows no benefit
Exercise
restriction offers no benefit
Delivery timing
Recommended at 37-39 weeks for those on
Antihypertensive
s (38-39 weeks if not on medications)
Management
Anti-hypertensives
See
Blood Pressure Management in Pregnancy
Goal: Lower Systolic
Blood Pressure
to <140/90
New goal as of 2022 (prior goal had been <150-160/100-110 mmHg, much higher than non-pregnant goal)
ACOG Practice Advisory
https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/04/clinical-guidance-for-the-integration-of-the-findings-of-the-chronic-hypertension-and-pregnancy-chap-study
Anti-hypertensives are now indicated for mild to moderate Chronic Hypertension in Pregnancy
Chronic
Hypertension
and Pregnancy (CHAP) Study found goal <140/90 benefits both mother and fetus
Tita (2022) N Engl J Med 386(19):1781-92 +PMID: 35363951 [PubMed]
Original studies found treatment of BP <150/100 did not reduce risk to fetus or prevent
Preeclampsia
Antihypertensive
s benefitted mother only (these do not reduce pregnancy complications)
Based on these findings, only severe chronic
Hypertension
(>150-160/100-110) was previously treated
References
van Dadelszen (2000) Lancet [PubMed]
(2001) Obstet Gynecol 98(1 suppl): 177-85 [PubMed]
Precautions
Aggressive lowering of
Blood Pressure
may result in adverse fetal outcomes (hypoperfusion)
Antihypertensive
used in pregnancy
Avoid contraindicated
Antihypertensive
s
Avoid
ACE Inhibitor
s and ARBs (serious fetal risk in second half of pregnancy, mixed data in first trimester)
Avoid
Atenolol
and
Beta Blocker
s in general (other than
Labetalol
) due to
IUGR
risk
Avoid
Spironolactone
,
Eplerenone
and
Aliskiren
Most commonly used
Antihypertensive
s in pregnancy
Labetolol 200 mg orally twice daily (up to 1200 mg twice daily)
Nifedipine
XL 30 mg orally twice daily (up to 120 mg daily)
Alpha Methyldopa
500 mg orally twice daily (up to 3000 mg daily in divided doses)
Long safety record, but weak
Antihypertensive
and less tolerated (
Fatigue
,
Dizziness
)
Also, as of 2023, indefinitely unavailable
Other
Antihypertensive
s used in pregnancy (less safety data)
Felodipine
5 mg PO daily (up to 20 mg daily)
Hydralazine
10 mg orally three times daily (up to 25 mg three times daily)
Hydrochlorothiazide
Not usually initiated in pregnancy due to volume depletion (esp. in first few weeks of starting)
May be continued if on pre-pregnancy (consult with local expert opinion)
Complications
Pregnancy Related
Superimposed
Preeclampsia
(17-25% for chronic
Hypertension
)
Placental Abruption
Intrauterine Growth Retardation
References
(2019) Am Fam Physician 100(12): 782-3 [PubMed]
(2012) Obstet Gynecol 119:396-407 [PubMed]
(2001) Obstet Gynecol 98(1 suppl): 177-85 [PubMed]
Farahi (2024) Am Fam Physician 109(3): 251-60 [PubMed]
Leeman (2008) Am Fam Physician 78: 93-100 [PubMed]
Leeman (2016) Am Fam Physician 93(2):121-7 [PubMed]
Seely (2014) Circulation 129(11): 1254-61 [PubMed]
Type your search phrase here